沙特肿瘤学会膀胱癌临床管理指南。
Saudi Oncology Society clinical management guidelines for urinary bladder cancer.
作者信息
Al Othman Khaled, Bazarbashi Shouki, Balaraj Khalid, Al Otaibi Mohamed, Kamal Baher, Al Oraifi Ibraheem, Al Saeed Eyad, Al Gamdi Khalid, Jubran Ali, Salah Ahmad, Al Shareef Jalal, Zekri Jamal
机构信息
Department of Urology, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.
出版信息
Urol Ann. 2011 Mar;3 Suppl(Suppl):S6-9. doi: 10.4103/0974-7796.78549.
Abstract
In this report guidelines for the evaluation, medical and surgical management of transitional cell carcinoma of urinary bladder is presented. It is categorized according to the stage of the disease using the tumor node metastasis staging system, 7(th) edition. The recommendations are presented with supporting level of evidence.
摘要
本报告介绍了膀胱移行细胞癌评估、医学及外科治疗的指南。根据疾病分期，采用第7版肿瘤淋巴结转移分期系统进行分类。推荐内容均给出了证据支持水平。
相似文献
1
Saudi Oncology Society clinical management guidelines for urinary bladder cancer.
Urol Ann. 2011 Mar;3 Suppl(Suppl):S6-9. doi: 10.4103/0974-7796.78549.
2
Saudi oncology society and Saudi urology association combined clinical management guidelines for urothelial urinary bladder cancer.
Urol Ann. 2014 Oct;6(4):273-7. doi: 10.4103/0974-7796.140941.
3
Saudi Oncology Society and Saudi Urology Association combined clinical management guidelines for urothelial cell carcinoma of the urinary bladder.
Urol Ann. 2016 Apr-Jun;8(2):131-5. doi: 10.4103/0974-7796.176873.
4
Saudi Oncology Society and Saudi Urology Association combined clinical management guidelines for urothelial cell carcinoma of the urinary bladder 2017.
Urol Ann. 2018 Apr-Jun;10(2):133-137. doi: 10.4103/UA.UA_176_17.
5
Saudi Oncology Society and Saudi Urology Association combined clinical management guidelines for renal cell carcinoma 2017.
Urol Ann. 2018 Apr-Jun;10(2):123-132. doi: 10.4103/UA.UA_175_17.
6
Saudi oncology society and Saudi urology association combined clinical management guidelines for renal cell carcinoma.
Urol Ann. 2014 Oct;6(4):286-9. doi: 10.4103/0974-7796.140974.
7
Saudi Oncology Society clinical management guidelines for renal cell carcinoma.
Urol Ann. 2011 Mar;3 Suppl(Suppl):S3-5. doi: 10.4103/0974-7796.78548.
8
Saudi Oncology Society and Saudi Urology Association combined clinical management guidelines for renal cell carcinoma.
Urol Ann. 2016 Apr-Jun;8(2):136-40. doi: 10.4103/0974-7796.179239.
9
Saudi oncology society and Saudi urology association combined clinical management guidelines for prostate cancer.
Urol Ann. 2014 Oct;6(4):278-85. doi: 10.4103/0974-7796.140959.
10
Saudi oncology society and Saudi urology association combined clinical management guidelines for testicular germ cell tumors.
Urol Ann. 2014 Oct;6(4):290-5. doi: 10.4103/0974-7796.140978.
本文引用的文献
1
Randomized phase II/III trial assessing gemcitabine/ carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer "unfit" for cisplatin-based chemotherapy: phase II--results of EORTC study 30986.
J Clin Oncol. 2009 Nov 20;27(33):5634-9. doi: 10.1200/JCO.2008.21.4924. Epub 2009 Sep 28.
2
EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder.
Eur Urol. 2008 Aug;54(2):303-14. doi: 10.1016/j.eururo.2008.04.051. Epub 2008 Apr 30.
3
The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial.
J Urol. 2006 May;175(5):1641-4. doi: 10.1016/S0022-5347(05)01002-5.
4
Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials.
Eur Urol. 2006 Mar;49(3):466-5; discussion 475-7. doi: 10.1016/j.eururo.2005.12.031. Epub 2006 Jan 17.
5
Adjuvant chemotherapy in muscle-invasive bladder carcinoma: a pooled analysis from phase III studies.
Cancer. 2006 Feb 15;106(4):783-8. doi: 10.1002/cncr.21676.
6
Management of stage T1 tumors of the bladder: International Consensus Panel.
Urology. 2005 Dec;66(6 Suppl 1):108-25. doi: 10.1016/j.urology.2005.08.066.
7
Bladder cancer: epidemiology, staging and grading, and diagnosis.
Urology. 2005 Dec;66(6 Suppl 1):4-34. doi: 10.1016/j.urology.2005.07.062.
8
Results of second-look resection after primary resection of T1 tumour of the urinary bladder.
Scand J Urol Nephrol. 2005;39(3):206-10. doi: 10.1080/00365590510007793-1.
9
Multivariate analysis of clinical parameters of synchronous primary superficial bladder cancer and upper urinary tract tumor.
J Urol. 2005 Sep;174(3):859-61; discussion 861. doi: 10.1097/01.ju.0000169424.79702.6d.
10
Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer.
J Clin Oncol. 2005 Jul 20;23(21):4602-8. doi: 10.1200/JCO.2005.07.757.
Zotero 插件